Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial

Hart, C. and Vogelhuber, M. and Hafner, C. and Landthaler, M. and Berneburg, M. and Haferkamp, S. and Herr, W. and Reichle, A. (2016) Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 30 (11). E119-E121. ISSN 0926-9959, 1468-3083

Full text not available from this repository. (Request a copy)
Item Type: Article
Uncontrolled Keywords: ;
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Dermatologie und Venerologie
Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)
Depositing User: Dr. Gernot Deinzer
Date Deposited: 22 Mar 2019 11:11
Last Modified: 22 Mar 2019 11:11
URI: https://pred.uni-regensburg.de/id/eprint/4051

Actions (login required)

View Item View Item